Importantly, further stratification analysis of patients with BRAF mutations, according to BRAF mutation type, revealed that similar OS (18.5 vs. 16.0, HR: 0.90; 95% CI, 0.37 to 2.20; p = 0.81), PFS (10.0 vs. 8.0, HR: 0.98; 95% CI, 0.47 to 2.00; p = 0.94) and ORR (51.7% vs. 31.1%; p = 0.17) between the BRAF V600E and Non-V600E NSCLC patients (Fig. 6G, H, Supplemental Table 4). Here, BRAF is linked to non-small cell lung carcinoma.